F1RST Up Alliance of Clinical Research Sites Focusing on Kidney Disease has Expanded to Include 55 Physician Investigators Representing 23 Sites

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Frenova Renal Research, the world’s only drug and medical device contract clinical development services provider dedicated exclusively to renal research, announced today that its F1RST Up™ alliance of clinical research sites focusing on kidney disease has expanded to include 55 physician-investigators representing 23 sites.

Kurt Mussina, general manager of Frenova, “The success of F1RST Up is clear evidence of the value the alliance provides to our sponsor clients, our alliance partners and to other contract research organizations (CROs) we collaborate with.” He went on to say, “F1RST Up accelerates study startup by taking a no-nonsense approach to driving low-value administrative and contracting burdens out of the startup process. This provides our partners and customers with a better startup experience, equating to much better value.”

The F1RST Up alliance membership includes nephrology practices caring for large numbers of chronic kidney disease (CKD) patients, including end-stage renal disease (ESRD) patients. F1RST Up investigators are highly experienced clinical researchers in renal disease and its adjacencies, including vascular access and care, cardio-renal conditions, rare diseases, infectious diseases and transplant. The alliance leverages Frenova’s access to proprietary clinical research assets to inform protocol design and to carry out highly targeted and efficient patient recruitment efforts.

On the formation of this alliance:  “We formed this alliance with the leading physician-investigators from across Frenova’s network of 260 clinical research sites,” said Christina Kahn, Frenova’s F1RST Up alliance lead. “This is important because it means F1RST Up offers sponsors access to a uniquely concentrated source of both high-quality renal research sites and a substantial number of patients.”

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.